These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20660574)

  • 21. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
    J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucose metabolism gene expression patterns and tumor uptake of ¹⁸F-fluorodeoxyglucose after radiation treatment.
    Wilson GD; Thibodeau BJ; Fortier LE; Pruetz BL; Galoforo S; Baschnagel AM; Chunta J; Oliver Wong CY; Yan D; Marples B; Huang J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):620-7. PubMed ID: 25304950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo evaluation of the effects of simultaneous inhibition of GLUT-1 and HIF-1α by antisense oligodeoxynucleotides on the radiosensitivity of laryngeal carcinoma using micro 18F-FDG PET/CT.
    Shen LF; Zhao X; Zhou SH; Lu ZJ; Zhao K; Fan J; Zhou ML
    Oncotarget; 2017 May; 8(21):34709-34726. PubMed ID: 28410229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
    Zhou LN; Wu N; Liang Y; Gao K; Li XY; Zhang LF
    World J Surg Oncol; 2015 Mar; 13():111. PubMed ID: 25888731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper.
    Jensen MM; Jørgensen JT; Binderup T; Kjaer A
    BMC Med Imaging; 2008 Oct; 8():16. PubMed ID: 18925932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
    J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
    Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
    Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in rat models with hepatocellular carcinoma with liver cirrhosis.
    Park SI; Lee JH; Ham HJ; Jung YJ; Park MS; Lee J; Maeng LS; Chung YA; Jang KS
    Biomed Mater Eng; 2015; 26 Suppl 1():S1669-76. PubMed ID: 26405933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
    Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
    Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET/CT in head and neck oncology: State-of-the-art 2013.
    Johnson JT; Branstetter BF
    Laryngoscope; 2014 Apr; 124(4):913-5. PubMed ID: 24515562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
    Benz MR; Herrmann K; Walter F; Garon EB; Reckamp KL; Figlin R; Phelps ME; Weber WA; Czernin J; Allen-Auerbach MS
    J Nucl Med; 2011 Nov; 52(11):1684-1689. PubMed ID: 22045706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic 2-Deoxy-2-[
    Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
    Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
    Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
    Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
    Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
    PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
    Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
    Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?
    Aukema TS; Kappers I; Olmos RA; Codrington HE; van Tinteren H; van Pel R; Klomp HM;
    J Nucl Med; 2010 Sep; 51(9):1344-8. PubMed ID: 20720059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.